Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus
NCT02856113 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus
- Lead sponsor
- Takeda
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 14, 2016
- Completion date
- February 14, 2022
- Enrollment
- 152 (actual)
- Sites
- 67
Conditions
As the registry lists them; a condition with its own page is linked.